Registration and Abstract Submission is now open for the 6th Australian Cancer Metabolism Meeting 2026!
Abstract deadline 20th April.
Registrations deadline 6th May.
Conference 20th-22nd May 2026
https://t.co/Krtol3hcFF
Personalized intensification of treatment for hormone-sensitive prostate cancer
https://t.co/S98ko2tEWm
Hormone-sensitive #ProstateCancer (HSPC) management has advanced beyond androgen-deprivation therapy (ADT) alone, now incorporating androgen receptor pathway inhibitors (ARPIs), docetaxel, and radiotherapy based on disease state and biology.
Modern PSMA PET imaging detects metastases earlier than conventional scans, redefining patient subgroups and influencing decisions such as when to use chemotherapy or radiotherapy. Treatment is increasingly personalized, guided by prior local therapy, PSA dynamics, disease volume, and imaging findings, with ARPI–ADT doublets forming the backbone for metastatic disease. Attention to toxicity from long-term testosterone suppression is crucial, while emerging biomarker-driven therapies—including ^177Lu-PSMA-617, AKT inhibitors, and PARP inhibitors—are poised to further refine care.
@drcilento@LisaButler5@drlouiseemmett@ChrisSweens1@OncoAlert 🚨
@Silke_Gillessen@AOmlin@weoncologists
Spent a fantastic week at @KULeuven as part of the Advisory Board for the @PROSTAMET Horizon EU Doctoral Student Network, hearing progress from the students and their projects. I left feeling very optimistic about this generation of students focused on #lipidmetabolism in PCa!
Exciting Masters/PhD opportunities in Adelaide Australia, balancing creativity, excellence and inclusion!! Please join if your interested in Genomics and making a difference through research!! Please share with your networks!!!